계명대학교 의학도서관 Repository

Statin therapy in acute cardioembolic stroke with no guidance-based indication

Metadata Downloads
Author(s)
Hong-Kyun Park Ji Sung Lee Keun-Sik Hong Yong-Jin Cho Jong-Moo Park Kyusik Kang Soo Joo LeeJae Guk Kim Jae-Kwan Cha Dae-Hyun KimHyun-Wook Nah Moon-Ku Han Beom Joon Kim Tai Hwan Park Sang-Soon ParkKyung Bok LeeJun LeeByung-Chul Lee Kyung-Ho Yu Mi Sun Oh Joon-Tae KimKang-Ho Choi Dong-Eog Kim Wi-Sun Ryu Jay Chol Choi Jee-Hyun Kwon Wook-Joo Kim Dong-Ick Shin Sung Il Sohn Jeong-Ho Hong Juneyoung Lee Philip B Gorelick Hee-Joon Bae
Keimyung Author(s)
Sohn, Sung IlHong, Jeong Ho
Department
Dept. of Neurology (신경과학)
Journal Title
Neurology
Issued Date
2020
Volume
94
Issue
19
Abstract
Objective:
It is uncertain whether patients with cardioembolic stroke and without a guidance-based indication for statin therapy should be administered a statin for prevention of subsequent vascular events. This study was performed to determine whether the statin therapy is beneficial in preventing major vascular events in this population.

Methods:
Using a prospective multicenter stroke registry database, we identified patients with acute cardioembolic stroke who were hospitalized between 2008 and 2015. Patients who had other established indications for statin therapy according to current guidelines were excluded. Major vascular event was defined as a composite of stroke recurrence, myocardial infarction, and vascular death. We performed frailty model analysis with the robust sandwich variance estimator using the stabilized inverse probability of treatment weighting method to estimate hazard ratios of statin therapy on outcomes.

Results:
Of 6,124 patients with cardioembolic stroke, 2,888 (male 44.6%, mean age 75.3 years, 95% confidence interval [CI] 74.8-75.8) were eligible, and 1,863 (64.5%) were on statin therapy during hospitalization. After a median follow-up of 359 days, cumulative incidences of major vascular events were 9.3% in the statin users and 20.5% in the nonusers (p < 0.001 by log-rank test). The adjusted hazard ratios of statin therapy were 0.39 (95% CI 0.31-0.48) for major vascular events, 0.81 (95% CI 0.57-1.16) for stroke recurrence, 0.28 (95% CI 0.21-0.36) for vascular death, and 0.53 (95% CI 0.45-0.61) for all-cause death.

Conclusion:
Starting statin during the acute stage of ischemic stroke may reduce the risk of major vascular events, vascular death, and all-cause death in patients with cardioembolic stroke with no guidance-based indication for statin.
Keimyung Author(s)(Kor)
손성일
홍정호
Publisher
School of Medicine (의과대학)
Citation
Hong-Kyun Park et al. (2020). Statin therapy in acute cardioembolic stroke with no guidance-based indication. Neurology, 94(19), e1984–e1995. doi: 10.1212/WNL.0000000000009397
Type
Article
ISSN
1526-632X
Source
https://n.neurology.org/content/94/19/e1984.long
DOI
10.1212/WNL.0000000000009397
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43254
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurology (신경과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.